Acquisitions (Narrative) (Details) (USD $) In Millions, unless otherwise specified	0 Months Ended	3 Months Ended
	Oct. 01, 2012	Dec. 27, 2013	Dec. 28, 2012
Business Acquisition [Line Items]
Cash payment, net of cash acquired		$ 0	$ 88.1
Net sales		540.2	504.0
CNS Therapeutics, Inc.
Business Acquisition [Line Items]
Contingent consideration	6.9
Contingent consideration, potential maximum	9.0
Specialty Pharmaceuticals | CNS Therapeutics, Inc.
Business Acquisition [Line Items]
Total consideration	95.0
Cash payment, net of cash acquired	88.1
Cash assumed in the acquisition	3.6
Contingent consideration	6.9
Contingent consideration, potential maximum	9.0
Assumptions used calculating in-process research and development, discount rate	35.00%
Net sales		7.6	6.5
In-process Research and Development | Specialty Pharmaceuticals | CNS Therapeutics, Inc.
Business Acquisition [Line Items]
Estimated cost to complete in-process research	$ 18.0